Most insurance plans either exclude weight loss drugs entirely or make them very difficult to get because of a combination of federal law, high drug prices, and a long-standing view that obesity is a lifestyle problem rather than a medical condition. The barriers differ depending on whether you have Medicare, Medicaid, or private insurance, but the result is often the same: you’re likely paying out of pocket for medications like Wegovy or Zepbound, which list at around $1,350 per month.
The Federal Law Behind Medicare’s Exclusion
If you’re on Medicare, the barrier is written directly into law. The Social Security Act defines what Medicare Part D can and cannot cover, and it specifically excludes “agents when used for anorexia, weight loss, or weight gain.” This isn’t a policy decision made by individual Medicare plans. It’s a blanket federal prohibition that no Medicare drug plan can override, regardless of how much weight you need to lose or what health conditions you have.
Medicaid follows a similar path. Federal rules allow states to exclude weight loss drugs from their formularies, and by default, every state’s Medicaid excluded drug list includes the same language about drugs used for weight loss. Some states have chosen to cover these medications anyway, but the federal framework makes exclusion the starting point rather than the exception.
Why Obesity Is Still Treated as a Lifestyle Issue
The deeper reason behind these exclusions is that U.S. health policy has historically treated obesity as a matter of personal behavior, not a chronic disease requiring medication. The American Medical Association didn’t formally recognize obesity as a disease until 2013. The federal government got there a bit earlier, in 2004, but the stigma has outlasted both declarations. Many policymakers, insurers, and even some clinicians still view weight as something people should manage through willpower, diet, and exercise.
That framing has real consequences for how treatments get covered. The Affordable Care Act, for example, encouraged health plans to cover lifestyle and behavioral counseling as the primary treatment for obesity, without requiring equivalent coverage for medications. The logic was that people should try changing their habits first. But clinical evidence tells a different story: the body’s own biological responses to weight loss, including shifts in hunger hormones and metabolism, often drive weight regain after diet and exercise alone. Clinical guidelines now recognize that lifestyle changes alone are often insufficient for people with obesity, which is part of why newer drugs like GLP-1 agonists have become so widely prescribed.
The Cost Problem for Insurers
Even when insurers acknowledge obesity as a medical condition, the price of these drugs creates a separate obstacle. Wegovy carries a list price of $1,350 per month. The actual price insurers pay after rebates and discounts is lower, but still substantial when multiplied across millions of potential patients.
The Institute for Clinical and Economic Review, an independent group that evaluates whether drug prices match their health benefits, found that semaglutide (the active ingredient in Wegovy) would only meet standard cost-effectiveness thresholds if priced between $7,500 and $9,800 per year after rebates. That’s roughly half or less of what many insurers currently pay, which gives them an economic argument for limiting coverage.
The Congressional Budget Office has estimated what would happen if Medicare began covering weight loss drugs starting in 2026: federal spending would increase by about $35 billion over nine years. That spending would be partially offset by $3.4 billion in savings from improved health outcomes, things like fewer heart attacks, less diabetes treatment, and fewer joint replacements. But the net cost of roughly $32 billion is enough to make legislators cautious. Annual costs would start at $1.5 billion in 2026 and rise to $6.1 billion by 2034 as more beneficiaries used the drugs.
What Private Insurance Actually Requires
Private insurers have more flexibility than Medicare, but most that do cover weight loss drugs put significant hurdles in place through prior authorization. A representative example comes from one major insurer’s criteria for Wegovy, Zepbound, and similar GLP-1 drugs. To get approved, you typically need to meet all of the following:
- BMI threshold: Either a BMI of 30 or higher, or a BMI of 27 or higher combined with at least one weight-related condition such as high blood pressure, type 2 diabetes, sleep apnea, heart disease, or liver disease.
- Prior lifestyle intervention: At least three months of documented behavioral modification and dietary changes before the insurer will consider medication.
- Ongoing requirements: You must continue diet and behavioral changes alongside the medication. The drug won’t be approved as a standalone treatment.
These requirements exist partly because insurers want to reserve expensive medications for people most likely to benefit, and partly because they reflect that older mindset of treating lifestyle changes as the first and primary intervention.
Employer Coverage Is Shifting, and Not Always Forward
Among large employers, coverage for GLP-1 weight loss drugs is growing but still limited. As of 2025, about 19% of companies with 200 or more employees cover these medications in their largest health plan. The number is higher at very large companies: 43% of firms with 5,000 or more workers now offer coverage, up from 28% just one year earlier.
But there’s a countertrend. Many employers that initially covered GLP-1 drugs for weight loss have started pulling back. Some have restricted coverage to employees who also have diabetes. Others have dropped weight loss coverage entirely after seeing how quickly costs grew as more employees began using the drugs. In employer focus groups, a common theme emerged: companies wanted to support employee health but couldn’t absorb the escalating pharmacy bills. This means your coverage could change from year to year depending on your employer’s cost calculations.
Legislation That Could Change Things
The most significant proposed change is the Treat and Reduce Obesity Act, reintroduced in Congress in July 2023. The bill would do two key things: expand Medicare coverage of behavioral obesity treatment to include more types of providers, and allow Medicare’s prescription drug benefit to cover medications used for obesity treatment and weight management. If passed, it would remove the longstanding statutory exclusion that currently blocks all Medicare coverage of weight loss drugs.
The bill was referred to committee but has not advanced to a vote. Similar versions have been introduced in previous sessions of Congress without passing, so the timeline for any change remains uncertain. In the meantime, the coverage landscape depends heavily on what type of insurance you have, who your employer is, and which state you live in.